Your browser doesn't support javascript.
loading
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.
Moses, Blake S; McCullough, Samantha; Fox, Jennifer M; Mott, Bryan T; Bentzen, Søren M; Kim, MinJung; Tyner, Jeffrey W; Lapidus, Rena G; Emadi, Ashkan; Rudek, Michelle A; Kingsbury, Tami J; Civin, Curt I.
Afiliação
  • Moses BS; Center for Stem Cell Biology & Regenerative Medicine and.
  • McCullough S; Department of Pediatrics, School of Medicine, University of Maryland, Baltimore, MD.
  • Fox JM; Center for Stem Cell Biology & Regenerative Medicine and.
  • Mott BT; Department of Pediatrics, School of Medicine, University of Maryland, Baltimore, MD.
  • Bentzen SM; Center for Stem Cell Biology & Regenerative Medicine and.
  • Kim M; Department of Pediatrics, School of Medicine, University of Maryland, Baltimore, MD.
  • Tyner JW; National Institutes of Health (NIH) Medical Scientist Training Program, School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Lapidus RG; Department of Epidemiology and Public Health and.
  • Emadi A; Marlene and Stewart Greenebaum Comprehensive Cancer Center, School of Medicine, University of Maryland, Baltimore, MD.
  • Rudek MA; Center for Stem Cell Biology & Regenerative Medicine and.
  • Kingsbury TJ; Department of Pediatrics, School of Medicine, University of Maryland, Baltimore, MD.
  • Civin CI; Department of Cell, Developmental and Cancer Biology and.
Blood Adv ; 5(3): 711-724, 2021 02 09.
Article em En | MEDLINE | ID: mdl-33560385
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artemisininas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artemisininas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article